Journal

Low-grade serous ovarian cancer: State of the science

Read time: 1 mins

Published:1st Mar 2020

Author: Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D et al.

Source: Gynecologic Oncology

Availability: Pay for access, or by subscription

Ref.:Gynecol Oncol. 2020 Mar;156(3):715-725.

DOI:10.1016/j.ygyno.2019.12.033

Low-grade serous ovarian cancer: State of the science

In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum–a rare ovarian cancer subtype that may arise de novo or following a diagnosis of serous borderline tumor. The purpose of the conference was to review current knowledge, discuss ongoing research by established researchers, and frame critical questions or issues for future directions. Following presentations and discussions, the primary objective was to initiate future collaborations, uniform database platforms, laboratory studies, and clinical trials to better understand this disease and to advance clinical care outside the boundaries of single academic institutions. This review summarizes the state of the science in five principal categories: epidemiology and patient outcomes, pathology, translational research, patient care and clinical trials, and patients' perspective.

Read abstract on library site Access full article